



V SIMPOSIO CACI@FAC

2º SESIÓN CONJUNTA CACI@GACI



29 – 30 de mayo 2014 | Mendoza

“Oclusión de la Orejuela Auricular Izquierda - Comentarios”

Dr. Aníbal Damonte

Departamento de Cardiología Intervencionista

Instituto Cardiovascular de Rosario

Rosario, Argentina



INSTITUTO CARDIOVASCULAR DE ROSARIO

Boulevard Oroño 450, 2000 Rosario, Argentina, Teléfono (0341) 4203040 - Fax (0341) 4203337


Registro RENAFA

Resultados. Estrategia tratamiento ACO

Sin contraindicaciones para anticoagulación



67.9% recibían anticoagulación



Alguna contraindicación para anticoagulación, a criterio del investigador*

Contraindicación	%
Edad avanzada	13.1
Sangrado activo	1.1
ACV hemorrágico	0.5
Limitación social	4.6
Imposibilidad control RIN	2.2
Caídas frecuentes	1.7
Rechazo paciente - familia	2.6
Coagulopatía	1.1
HTA no controlada	0.3

Medico a cargo de ACO	%
Cardiólogo	31.4
Hematólogo	53.9
Clínico	1.3
Medico cabecera	3.2
NS-NC	10.2

*Nota: de estos, 65.4% recibían antiagregantes




V SIMPOSIO CACI@FAC

2º SESIÓN CONJUNTA CACI@GACI



29 – 30 de mayo 2014 | Mendoza

- 500,000 strokes per year
- 15 – 20% of strokes/year are related to AF
- Functional Impact of AF-Related Stroke:



Sources: *Neurology*, 1978; *Stroke*, 1985; *European Heart Journal*, 1987; *Lancet*, 1987; *Fisher. Geriatrics*. 1979;34:59



V SIMPOSIO


CACI@FAC

2º SESIÓN CONJUNTA CACI@GACI



29 – 30 de mayo 2014 | Mendoza

Swedish Stroke Registry





V SIMPOSIO


CACI@FAC

2º SESIÓN CONJUNTA CACI@GACI



29 – 30 de mayo 2014 | Mendoza

Oral Anticoagulants DISCONTINUATION RATES





V SIMPOSIO


CACI@FAC

2º SESIÓN CONJUNTA CACI@GACI



29 – 30 de mayo 2014 | Mendoza

Estudio de cohorte de 82854 pac en Dinamarca (13573 presentaron sangrado fatal o no fatal en el seguimiento a 2,6 años)



“Percutaneous closure of the left atrial appendage: Initial Experience in Latin America”

Coauthors and Participating Hospitals



- Dr. C Pedra, Dra. L Armaganijan; Instituto Dante Pazzanese, San Pablo, Brasil
Dr. C Costantini, Hospital Cardiológico Costantini, Curitiba, Brasil
Dr. M Montenegro, Dr. E Quintella, Instituto Estadual de Cardiologia, Río de Janeiro, Brasil
Dr. Alejandro Martinez, Universidad Católica de Chile, Santiago, Chile
Dr. Fabio Brito, Dr. M Perin, Hospital Albert Einstein, San Pablo, Brasil
Dr. José Condado, Hospital Perez Carreño, Caracas, Venezuela
Dr. Daniel Aguirre, Clínica Alemana, Santiago, Chile
Dr. Horacio Faella, Dr. Germán Henestrosa, Instituto FLENI, Buenos Aires, Argentina
Dr. León Valdivieso, Dr. Oscar Mendiz, Fundación Favaloro, Buenos Aires, Argentina
Dr. C Pincetti, Dr. L Romero, Hospital Regional de Temuco, Chile
Dr. C Deck, Dr. Polentzi Uriarte, Instituto Clínico del torax, Santiago, Chile
Dr. Miguel Ballarino, Dr. Alejandro Peirone, Hospital Privado, Córdoba, Argentina
Dr. Fernando Cura, Dr. Sebastian Peralta, Instituto Cardiovascular de Buenos Aires, Argentina
Dr. Alejandro Fernandez, Dr. Daniel Berrocal, Hospital Italiano, Buenos Aires, Argentina
Dr. Alejandro Palacios, Dr. Juan Arellano, Sanatorio de la Trinidad, Buenos Aires, Argentina
Dr. R LLuberas, Dr. Alvaro Rivara, Hospital de Clínicas, Montevideo, Uruguay
Dr. Mauricio Scanavacca, INCOR, San Pablo, Brasil
Dr. Aníbal Damonte, Dr. Eduardo Picabea, Instituto Cardiovascular de Rosario, Argentina.


Objectives

This study describes the feasibility, in hospital, and follow up results of the transcatheter closure of the left atrial appendage (LAA) with the Amplatzer Cardiac Plug (ACP) in an initial Latin American experience.

Results

N=60, June 2012

Procedures / Country



■ Brazil ■ Argentina ■ Chile ■ Venezuela ■ Uruguay



Results

- Age $72 \pm 8,7$
 - Male 70 %
 - HTA 78 %
 - DBT 17 %
 - CHF 32,17 %
 - Contraindic. ACO 64,29 %

 - **CHADS2 score** $3,15 \pm 1,12$
-

In Hospital and FU Results

Successful Implant	60 (100%)
Simultaneous PFO Closure	3 (5%)

- In hospital Complications:


5 patients (8,3%)

1 embolization (retrieved surgically)

4 severe pericardial effusions – pericardiocentesis (6,6%)

No death, stroke or myocardial ischaemia.

Duration of Hospitalization
with and w/out SPE



- Patients were discharged on DAT.
- No new events were reported at 30 days clinical follow up. 88% of patients underwent TEE at 30-45 days without evidence of flow to the LAA or thrombus on device.

Results




	Protect AF ⁽¹⁾ N= 463	Protect AF(early) ⁽¹⁾ N=271	ACPIIn.Eu.Ex ⁽²⁾ N= 143	ACP LatAm N= 60
Successfull implant (%)	90.9	88.2	96.4	100
Severe peric. effussion (%)	5.0	6.3	3.5	6.6
Emboliztion of device (%)	0.2	N/A	1.4	1.6
Stroke/TIA (%)	0.9	1.1	2.1	0
Major complic. (%)	7.7	10	7.0	8.3

⁽¹⁾Reddy V, et al. *Circ* 2011;123:417-424

⁽²⁾Park J, et al. *CCI* 2011;77:701-706

Results at Follow Up



- Mean CHADS2 score 3,15
- Expected annual risk of stroke 5,9%
- Strokes at F/Up (Me 12,5 months) 0

CACI



V SIMPOSIO

CACI@FAC

2º SESIÓN CONJUNTA CACI@GACI



29 – 30 de mayo 2014 | Mendoza



V SIMPOSIO CACI@FAC

2º SESIÓN CONJUNTA CACI@GACI



29 – 30 de mayo 2014 | Mendoza

Patient Population per Country

(per 2010)	Population (million)	AF patients (x 1000)	Pts at High Risk for Stroke	Pts. NOT on Anticoagulation	Contraindicated Anticoagulation	Bleeding Complications (from total)	Bleeding complications (from treated)
US	311	2315	1736	868	260	52.1	26.0
Australia	22.6	168	126	63	19	3.8	1.9
Canada	34.4	256	192	96	29	5.8	2.9
Japan	128	953	715	357	107	21.4	10.7
EUROPE	508	3783	2837	1418	426	85	43
Austria	8.4	65	47	25	7	1.4	0.7
Belgium	10.8	80	60	30	9	1.8	0.9
Czech Republic	10.5	78	59	29	9	1.8	0.9
Denmark	5.6	42	31	16	5	0.9	0.5
Finland	5.3	39	30	15	4	0.9	0.4
France	65.8	490	367	184	55	11.0	5.5
Germany	81.8	609	457	228	68	13.7	6.8
Greece	11.3	84	63	32	9	1.9	0.9
Italy	60.6	451	338	169	51	10.1	5.1
Ireland	4.5	33	25	13	4	0.8	0.4
Netherlands	16.6	124	93	46	14	2.8	1.4
Norway	5.0	37	28	14	4	0.8	0.4
Poland	38.1	284	213	106	32	6.4	3.2
Portugal	10.6	79	59	30	9	1.8	0.9
Spain	46.2	344	258	129	39	7.7	3.9
Sweden	9.4	70	52	26	8	1.6	0.8
Switzerland	7.8	58	44	22	7	1.3	0.7
UK	62.0	461	346	173	52	10.4	5.2
West Balkan	20.9	156	117	58	18	3.5	1.8
Other	27	201	151	75	23	4.5	2.3
Percentage	Baseline	7443 pts.million-1	78%	50%	15%	3%	3%
Reference		1	2	3	4	5	5

1. 2.3 million patients suffer from AF in the US, 4 million in EU - Fuster et al, ACC/AHA/ESC Practice Guidelines, Circulation, 2006;114:700-752.
2. 75% of patients are at high level of stroke (Euroheart survey, Birmingham/NICE score, CHADS2 = 75% high & intermediate), Lip et al., CHEST Feb 2010 vol. 137 no. 2 26S-272
3. Anticoagulant is not used (not prescribed and/or not taken), upto 60% of pts Gladstone et al, Stroke, 2009; 40:235-240
4. The prevalence of contraindications is around 15% of clinical AF patients, Njauwlaar R, et al. Euroheart Survey, European Heart Journal (2005) 26, 2422-2434
5. Major bleeding rate 3.36%/yr in warfarin group, 2.71%/year - 110 mg of Dabigatran and 3.11%/year - 150 mg of Dabigatran, Connolly, N Engl J Medicine 2009; DOI:10.1056/NEJMoa0905561